MedTrace Logo

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

NCT02160626 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2019-01-03

Study results available
· View outcomes & findings →

Summary

The main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101 solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101 Solution Vehicle.

Conditions

  • Seborrheic Keratosis

Interventions

DRUG

A-101 Vehicle

Placebo control

DRUG

A-101 (40) Topical Solution

A-101 (40) Topical Solution - high dose

DRUG

A-101 (32.5) Topical Solution

A-101 (32.5) Topical Solution - low dose

Sponsors & Collaborators

  • Aclaris Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jonathan S Weiss, MD · Gwinnett Clinical Research Center, Inc.

  • Janet Dubois, MD · Derm Research, PLLC

  • David C Wilson, MD · The Education & Research Foundation, Inc.

  • Daniel M Stewart, DO · Michigan Center for Research Corp.

  • Andrew Blauvelt, MD, MBA · Oregon Medical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02160626 on ClinicalTrials.gov